Abstracts tagged "osteoporosis"

Abstract Number: 2527 • ACR Convergence 2023
Risk Factors for Bone Loss in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: Osteoporotic fractures are the most common damage item from the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index. Previous…
Abstract Number: 1072 • ACR Convergence 2023
Increase in Major Osteoporotic Fractures After Therapy with Immune Checkpoint Inhibitors
Maria Suarez-Almazor¹, Carrie Ye², Bo Zhao³, Juan Ruiz³, Hui Zhao³, Noha Abdel-Wahab⁴ and William Leslie⁵, ¹MD Anderson Cancer Center, Houston, TX, ²University of Alberta, Edmonton, AB, Canada, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴University of Texas MD Anderson Cancer Center, Houston, TX, ⁵University of Manitoba, Internal Medicine, Winnipeg, MB, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. Despite their efficacy on tumor outcomes they can cause severe and sometimes long-standing immune-related…
Abstract Number: 2007 • ACR Convergence 2023
Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study
Insa Mannstadt, Donald McMahon, Douglas Mintz, Weija Yuan, Linda Russell, Susan Goodman, Emily Stein and Dalit Ashany, Hospital for Special Surgery, New York, NY
Background/Purpose: Axial spondyloarthritis (AxSpA), a chronic inflammatory rheumatic disease causes abnormal bone growth at the spine and paradoxically has been linked to osteoporosis and fragility…
Abstract Number: 2528 • ACR Convergence 2023
Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
Min Kim¹, Vanessa C. Brunetti¹, Felicia Cosman², Jeffrey Curtis³, E Michael Lewiecki⁴, Matthew Phelan⁵, Peter Samai⁵, Michele McDermott¹, Tzu-Chieh Lin¹, M Alan Brookhart⁶ and Kathleen Hurwitz⁵, ¹Amgen, Inc., Thousand Oaks, CA, ²Columbia University, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵Target RWE, Durham, NC, ⁶Department of Population Health Sciences, Duke University, Durham, NC
Background/Purpose: Recent studies suggest that post-fracture pharmacologic management has been declining in the U.S. despite an increase in the burden of osteoporosis (OP). In light…
Abstract Number: 1098 • ACR Convergence 2023
Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Kelly Tran¹, Ellen Ann Sockman¹, Rachel Salyer¹, Megan Young¹, Aisha Abbasi¹ and Devanshu Verma², ¹West Virginia University Hospital, Morgantown, WV, ²West Virginia University, Morgantown, WV
Background/Purpose: Osteoporosis is a medical condition associated with decreased bone mass and bone architecture, which increases incidence of fragility fractures(4). It is associated with 1.5…
Abstract Number: 2008 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Jeffrey Curtis¹, Tarun Arora², Ye Liu¹, Tzu-Chieh Lin³, Leslie Spangler³, Vanessa C. Brunetti³, Robert K. Stad³, Michele McDermott³, Brian D. Bradbury³ and Min Kim³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than oral bisphosphonates, evidence is lacking…
Abstract Number: 2529 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Jeffrey R Curtis¹, Tarun Arora², Ye Liu³, Vanessa C. Brunetti⁴, Tzu-Chieh Lin⁴, Leslie Spangler⁴, Robert K. Stad⁴, Michele McDermott⁴, Brian D. Bradbury⁴ and Min Kim⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from…
Abstract Number: 1620 • ACR Convergence 2023
Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab
Ye Liu¹, Tarun Arora², S. Bobo Tanner³ and Jeffrey Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Romosozumab (romo) and denosumab (dmab) are recommended for postmenopausal women with osteoporosis (OP) at high risk of fracture. The U.S. prescribing information includes a…
Abstract Number: 2009 • ACR Convergence 2023
Screening and Treatment of Low Bone Mineral Density in Allogeneic Hematopoietic Cell Transplant Patients
Perry Fuchs, Christina Ferraro, Chao Zhang, Chad Deal, Betty Hamilton and Sarah Keller, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Bone mineral density (BMD) loss and fracture are important causes of increased morbidity following allogeneic hematopoietic stem cell transplant (allo-HCT).Recent societal recommendations support screeningDual…
Abstract Number: 2530 • ACR Convergence 2023
Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center
Sarah Keller¹, Adil Vural², Jennifer Varley², Komal Mushtaq², Walaa Abu Alya³, Neel Tapryal², Hassan Shaheen³, Marie Budev², Abby Abelson² and Chad Deal¹, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic Fairview Hospital, Cleveland, OH
Background/Purpose: Osteoporotic fractures are a well-known complication in LT recipients, significantly impacting their quality of life. Specific risk factors for these fractures in LT recipients…
Abstract Number: 1719 • ACR Convergence 2023
Exploring the Link Between Osteitis and Bone Microstructure Changes in Rheumatoid Arthritis: Role of JAK-STAT Signaling Pathway
Tsuneyasu Yoshida¹, Yoichi Nakayama¹, Masao Katsushima², Yuri Nishida³, Mirei Shirakashi¹, Ran Nakashima¹, Ryu Watanabe², Kosaku Murakami⁴, Hajime Yoshifuji¹, Akio Morinobu¹ and Motomu Hashimoto², ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan, ³Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan, ⁴Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Osteitis on MRI and bone microstructure changes (BMC) on high-resolution peripheral quantitative CT are the earliest signs of arthritis, preceding the development of bone…
Abstract Number: 2010 • ACR Convergence 2023
B-FROST: Chronic OBstructive Pulmonary Disease and Vertebral FRacture of OSTeoporotic Origin: Results of a Real-life Cohort
Amine Mouamnia, Armentieres Hospital Center, Armentieres, France
Background/Purpose: Chronic obstructive pulmonary disease (COPD) is a chronic disease of the airways. It is mainly caused by smoking. Active smoking is a risk factor…
Abstract Number: 2531 • ACR Convergence 2023
Proton Pump Inhibitor Use Is Associated with Impaired Bone Mineral Density but Not Bone Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Taking Glucocorticoids
Andriko Palmowski¹, Gabriela Schmajuk², Jinoos Yazdany³, Patti Katz⁴, Jing Li⁵, Rachael Stovall⁵, Emma Kersey⁵, Sabrina Mai Nielsen⁶, Robin Christensen⁷, Henning Bliddal⁸, Zhivana Boyadzhieva⁹, Udo Schneider⁹, Tobias Alexander¹⁰, Burkhard Muche¹¹, Sandra Hermann¹¹, Edgar Wiebe¹¹ and Frank Buttgereit¹¹, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²UCSF / SFVA, San Francisco, CA, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of California San Francisco, San Rafael, CA, ⁵University of California San Francisco, San Francisco, CA, ⁶The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁷Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ⁸The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ⁹Charité Universitatsmedizine - Berlin, Berlin, Germany, ¹⁰Charité Universiätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany, ¹¹Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at increased risk of osteoporosis and fragility fractures. For this population, whether proton pump inhibitor…
Abstract Number: 1818 • ACR Convergence 2023
Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S
Ye Liu¹, Tarun Arora², Jeffrey Curtis¹ and Jingyi Zhang¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL
Background/Purpose: Romosozumab (romo) is a newly approved osteoporosis (OP) medicine for women with postmenopausal OP at high risk of fracture. The utilization pattern of romo…
Abstract Number: 2011 • ACR Convergence 2023
Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis
Nicholas Rossi¹, Aamir Saeed², Aqib Khan³, Hamzah Amin², Ummaz Nadeem², Zain Sultan³ and Marwan Bukhari², ¹University Hospitals of Morecambe Bay Foundation Trust, Worksop, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe Bay Foundation Trust, Lancaster, United Kingdom
Background/Purpose: Osteoporosis (OP) presents with fragility fractures, which can cause significant disability and cost to health services globally. There has been extensive research looking at…

« Previous Page
1
…
3
4
5
6
7
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].